Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.

Also called NCT02968368

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 167 participants (enrolled count) (from the registry)
Sponsor
Shield Therapeutics (from the registry)
Registry
  • NCT NCT02968368
Other papers using this trial's data
  • Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021-12 DOI, PubMed 34029682

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02968368. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-01 (actual); primary completion 2018-01-18 (actual). Results posted on 2020-05-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
Acronym
AEGIS-CKD
Condition
Renal Insufficiency, Chronic
Condition
Iron-Deficiency Anemia
Intervention (Drug)
Ferric maltol
Intervention (Other)
Placebo
Lead sponsor
Shield Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02968368
Content hash
b715c27e0c34df066ae154163dfbe39c02b5311f1ab2155463db378e384c0dc0